These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26811674)

  • 1. Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot study.
    Ohnuma T; Toda A; Kimoto A; Takebayashi Y; Higashiyama R; Tagata Y; Ito M; Ota T; Shibata N; Arai H
    Clin Interv Aging; 2016; 11():29-36. PubMed ID: 26811674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease.
    Sharma A; Bemis M; Desilets AR
    Am J Alzheimers Dis Other Demen; 2014 Aug; 29(5):409-14. PubMed ID: 24413538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
    Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
    Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer's disease.
    Ota M; Matsuo J; Ishida I; Takano H; Yokoi Y; Hori H; Yoshida S; Ashida K; Nakamura K; Takahashi T; Kunugi H
    Neurosci Lett; 2019 Jan; 690():232-236. PubMed ID: 30367958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease.
    Henderson ST; Morimoto BH; Cummings JL; Farlow MR; Walker J
    J Alzheimers Dis; 2020; 75(2):547-557. PubMed ID: 32310169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study.
    Buschert VC; Friese U; Teipel SJ; Schneider P; Merensky W; Rujescu D; Möller HJ; Hampel H; Buerger K
    J Alzheimers Dis; 2011; 25(4):679-94. PubMed ID: 21483095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
    Kennelly S; Abdullah L; Kenny RA; Mathura V; Luis CA; Mouzon B; Crawford F; Mullan M; Lawlor B
    Int J Geriatr Psychiatry; 2012 Apr; 27(4):415-22. PubMed ID: 21560164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer's disease: protocol for a randomized controlled trial.
    Chua KK; Wong A; Kwan PW; Song JX; Chen LL; Chan AL; Lu JH; Mok V; Li M
    Trials; 2015 Apr; 16():199. PubMed ID: 25925312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.